JP2021506244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506244A5 JP2021506244A5 JP2020531955A JP2020531955A JP2021506244A5 JP 2021506244 A5 JP2021506244 A5 JP 2021506244A5 JP 2020531955 A JP2020531955 A JP 2020531955A JP 2020531955 A JP2020531955 A JP 2020531955A JP 2021506244 A5 JP2021506244 A5 JP 2021506244A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- set forth
- sequence set
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims 5
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 238000011357 CAR T-cell therapy Methods 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 102000048432 human TREM2 Human genes 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111639A JP2023134582A (ja) | 2017-12-12 | 2023-07-06 | 抗ｔｒｅｍ２抗体及び関連する方法 |
| JP2025081613A JP2025109867A (ja) | 2017-12-12 | 2025-05-15 | 抗ｔｒｅｍ２抗体及び関連する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597827P | 2017-12-12 | 2017-12-12 | |
| US62/597,827 | 2017-12-12 | ||
| US201862648089P | 2018-03-26 | 2018-03-26 | |
| US62/648,089 | 2018-03-26 | ||
| PCT/US2018/065026 WO2019118513A1 (en) | 2017-12-12 | 2018-12-11 | Anti-trem2 antibodies and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111639A Division JP2023134582A (ja) | 2017-12-12 | 2023-07-06 | 抗ｔｒｅｍ２抗体及び関連する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506244A JP2021506244A (ja) | 2021-02-22 |
| JP2021506244A5 true JP2021506244A5 (https=) | 2022-01-11 |
| JP7311512B2 JP7311512B2 (ja) | 2023-07-19 |
Family
ID=66820649
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531955A Active JP7311512B2 (ja) | 2017-12-12 | 2018-12-11 | 抗ｔｒｅｍ２抗体及び関連する方法 |
| JP2023111639A Pending JP2023134582A (ja) | 2017-12-12 | 2023-07-06 | 抗ｔｒｅｍ２抗体及び関連する方法 |
| JP2025081613A Pending JP2025109867A (ja) | 2017-12-12 | 2025-05-15 | 抗ｔｒｅｍ２抗体及び関連する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111639A Pending JP2023134582A (ja) | 2017-12-12 | 2023-07-06 | 抗ｔｒｅｍ２抗体及び関連する方法 |
| JP2025081613A Pending JP2025109867A (ja) | 2017-12-12 | 2025-05-15 | 抗ｔｒｅｍ２抗体及び関連する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10508148B2 (https=) |
| EP (1) | EP3723803A4 (https=) |
| JP (3) | JP7311512B2 (https=) |
| KR (1) | KR102860409B1 (https=) |
| CN (1) | CN111712258B (https=) |
| AU (1) | AU2018383709B2 (https=) |
| BR (1) | BR112020011833A2 (https=) |
| CA (1) | CA3083660A1 (https=) |
| CL (2) | CL2020001575A1 (https=) |
| CR (1) | CR20200303A (https=) |
| DO (1) | DOP2020000128A (https=) |
| IL (2) | IL321287A (https=) |
| MX (1) | MX2020006213A (https=) |
| PE (1) | PE20200862A1 (https=) |
| PH (1) | PH12020550860A1 (https=) |
| SG (1) | SG11202005484VA (https=) |
| WO (1) | WO2019118513A1 (https=) |
| ZA (1) | ZA202105676B (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| US20190321443A1 (en) * | 2016-02-16 | 2019-10-24 | President And Fellows Of Harvard College | Modulators of MS4A activity |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| AU2018383709B2 (en) | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| KR20210104079A (ko) * | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551228A1 (en) * | 2019-11-22 | 2023-06-14 | Lilly Co Eli | Trem2 antibodies and uses thereof |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| IL272390A (en) * | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| CN111184742B (zh) * | 2020-02-13 | 2022-06-24 | 中山大学附属第五医院 | Trem-2+t细胞在制备用于治疗结核病药物中的应用 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| IL285416A (en) * | 2021-08-05 | 2023-03-01 | Yeda Res & Dev | Antibodies for cancer treatment |
| EP4405385A1 (en) * | 2021-09-21 | 2024-07-31 | Quell Therapeutics Limited | Anti-trem2 chimeric antigen receptor |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN118647631A (zh) * | 2021-11-29 | 2024-09-13 | 开拓免疫医疗公司 | 用抗trem2抗体治疗纤维化 |
| JP2025503437A (ja) | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CN115819552B (zh) * | 2022-07-07 | 2025-04-25 | 厦门大学 | 一种多肽在制备防治阿尔茨海默病药物/试剂中的用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025015713A1 (zh) * | 2023-07-19 | 2025-01-23 | 成都优洛生物科技有限公司 | 抗trem2人源化抗体、其抗原结合片段及其应用 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| WO2025030887A1 (zh) * | 2023-08-09 | 2025-02-13 | 成都优洛生物科技有限公司 | 抗trem2纳米抗体或其抗原结合片段及应用 |
| KR20260051042A (ko) | 2023-08-09 | 2026-04-15 | 에프. 호프만-라 로슈 아게 | 단일 및 다중특이성 항-trem2 항체, 그 방법 및 용도 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN119735683B (zh) * | 2023-12-21 | 2025-10-31 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025245092A1 (en) * | 2024-05-20 | 2025-11-27 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US12545729B2 (en) * | 2024-06-27 | 2026-02-10 | Mabwell Therapeutics, Inc. | Anti-TREM2 agonist antibodies and antigen-binding fragments thereof that can increase levels of soluble TREM2 in serum and brain tissue |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN119345178A (zh) * | 2024-10-31 | 2025-01-24 | 北京大学 | 紫杉醇联合trem2抑制剂在制备乳腺癌治疗药物中的应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294331B2 (en) | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| AU3958101A (en) | 2000-03-15 | 2001-09-24 | Univ Pohang | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
| EP2478760A1 (en) * | 2005-05-10 | 2012-07-25 | Monsanto Technology LLC | Genes and uses for plant improvement |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| US20090202544A1 (en) | 2006-02-02 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Methods of Treating Diseases by Targeting Silt3 |
| CA2655903A1 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR101773216B1 (ko) * | 2009-12-29 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ27 항체 |
| CA2793657A1 (en) | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012149416A2 (en) | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013033734A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
| JP6411333B2 (ja) | 2012-05-24 | 2018-10-24 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン |
| WO2014025828A1 (en) * | 2012-08-06 | 2014-02-13 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| EP2977386A1 (en) | 2012-08-31 | 2016-01-27 | Argen-X Nv | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| CA2890571A1 (en) * | 2012-11-07 | 2014-05-15 | Kenneth G. Geles | Anti-notch3 antibodies and antibody-drug conjugates |
| WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| ES2860952T3 (es) | 2013-08-01 | 2021-10-05 | Univ Catholique Louvain | Proteína anti-garp y usos de la misma |
| WO2015035365A1 (en) | 2013-09-09 | 2015-03-12 | The Nohns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CA2955086A1 (en) * | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| WO2016064895A1 (en) | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| CA2972048C (en) | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| WO2016125017A1 (en) | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| DK3354729T5 (da) | 2015-09-24 | 2024-09-30 | Daiichi Sankyo Co Ltd | Anti-garp-antistof |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| MX2018013038A (es) | 2016-04-27 | 2019-03-28 | Pfizer | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. |
| CN109641961A (zh) | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CN107733598B (zh) | 2016-08-11 | 2021-04-06 | 中国移动通信有限公司研究院 | 一种消息传输方法、用户设备及基站 |
| CN109641685B (zh) | 2016-08-30 | 2024-07-16 | 肖勒Ipn公司 | 用于柔性袋的喷嘴和具有喷嘴的柔性袋 |
| US10167796B2 (en) | 2017-05-17 | 2019-01-01 | GM Global Technology Operations LLC | Gasoline particulate filter regeneration strategy |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| AU2018383709B2 (en) | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| KR20210104079A (ko) | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
-
2018
- 2018-12-11 AU AU2018383709A patent/AU2018383709B2/en active Active
- 2018-12-11 MX MX2020006213A patent/MX2020006213A/es unknown
- 2018-12-11 BR BR112020011833-8A patent/BR112020011833A2/pt unknown
- 2018-12-11 IL IL321287A patent/IL321287A/en unknown
- 2018-12-11 CN CN201880089137.5A patent/CN111712258B/zh active Active
- 2018-12-11 JP JP2020531955A patent/JP7311512B2/ja active Active
- 2018-12-11 SG SG11202005484VA patent/SG11202005484VA/en unknown
- 2018-12-11 KR KR1020207019802A patent/KR102860409B1/ko active Active
- 2018-12-11 CR CR20200303A patent/CR20200303A/es unknown
- 2018-12-11 PE PE2020000759A patent/PE20200862A1/es unknown
- 2018-12-11 WO PCT/US2018/065026 patent/WO2019118513A1/en not_active Ceased
- 2018-12-11 CA CA3083660A patent/CA3083660A1/en active Pending
- 2018-12-11 IL IL275073A patent/IL275073B2/en unknown
- 2018-12-11 EP EP18887815.1A patent/EP3723803A4/en active Pending
-
2019
- 2019-05-09 US US16/408,322 patent/US10508148B2/en active Active
- 2019-10-14 US US16/601,233 patent/US11505602B2/en active Active
-
2020
- 2020-06-10 PH PH12020550860A patent/PH12020550860A1/en unknown
- 2020-06-11 CL CL2020001575A patent/CL2020001575A1/es unknown
- 2020-06-19 DO DO2020000128A patent/DOP2020000128A/es unknown
-
2021
- 2021-02-03 CL CL2021000293A patent/CL2021000293A1/es unknown
- 2021-08-11 ZA ZA2021/05676A patent/ZA202105676B/en unknown
-
2022
- 2022-10-07 US US18/045,093 patent/US12428481B2/en active Active
-
2023
- 2023-07-06 JP JP2023111639A patent/JP2023134582A/ja active Pending
-
2025
- 2025-05-15 JP JP2025081613A patent/JP2025109867A/ja active Pending
- 2025-08-20 US US19/305,631 patent/US20260042837A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506244A5 (https=) | ||
| JP7442443B2 (ja) | 多重特異性抗体 | |
| KR102907326B1 (ko) | Cd137을 표적화하는 항체 및 이의 사용 방법 | |
| AU2017414149B2 (en) | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) | |
| JP2024050684A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| EP3470426A1 (en) | Multispecific antibody | |
| CN102131828B (zh) | 针对人程序性死亡受体pd-1的抗体 | |
| EP4347655A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| CN113573728A (zh) | 治疗性SIRPα抗体 | |
| CA3196809A1 (en) | Combination treatment | |
| JP2022514734A5 (https=) | ||
| JP2024530451A (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用 | |
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| CN117551197A (zh) | 激动性cd40抗体 | |
| US20250171534A1 (en) | Anti-lilrb1/2 antibodies and uses thereof | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| JP2022553927A (ja) | Ｉｌｔ－２阻害剤での癌の処置 | |
| CA3221866A1 (en) | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JP2022523145A5 (https=) |